Symptomtext
administered quadracel to a 6 month old child instead of DTAP with no reported adverse event; Initial information was received from PRIVACY on 28-Nov-2023 regarding an unsolicited valid non-serious case received from a consumer/non-health-care professional. This case involves 6 months old female patient who experienced administered quadracel to a 6 month old child instead of dtap with no reported adverse event while receiving vaccines DIPHTHERIA-15/TETANUS/5 HYBRID AC PERTUSSIS/ipv (VERO) VACCINE [Quadracel (VERO)] and diphtheria-15/tetanus/5 hybrid ac pertussis/ipv (mrc5) vaccine [Quadracel]. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. Concomitant medications included pneumococcal vaccine CONJ 20V (CRM197) (Prevnar 20) for Immunisation. On an unknown date, the patient received a unknown dose of suspect diphtheria-15/tetanus/5 hybrid ac pertussis/ipv (mrc5) vaccine(suspension for injection) strength, expiry date, lot number not reported via unknown route in unknown administration site for prophylactic vaccination (Immunization).The information on batch umber was requested. On 06-Nov-2023, the patient received a dose 1 of 0.5 ml of suspect DIPHTHERIA-15/TETANUS/5 HYBRID AC PERTUSSIS/ipv (VERO) VACCINE (Solution for injection in pre-filled syringe) lot U7931AB, Expiry date : 09-Nov-2025, strength was unknown via intramuscular route in the left thigh for prophylactic vaccination (Immunization). On 06-Nov-2023 the patient was administered quadracel to a 6 month old child instead of dtap with no reported adverse event (wrong product administered) (latency: same day). Action taken with DIPHTHERIA, TETANUS, AC PERTUSSIS and ipv VACCINE (Quadracel) and DIPHTHERIA, TETANUS, AC PERTUSSIS and ipv VACCINE (Quadracel (VERO)) was not applicable. At time of reporting, the outcome was Unknown for the event administered quadracel to a 6 month old child instead of dtap with no reported adverse event. Action taken: not applicable. Outcome: Unknown for the event. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.